Lipigon Pharmaceuticals AB (publ) reported earnings results for the third quarter and nine months ended September 30, 2021. For the third quarter, the company reported sales was SEK 0.604 million compared to SEK 2.04 million a year ago. Revenue was SEK 0.749 million compared to SEK 2.14 million a year ago. Net loss was SEK 11.43 million compared to SEK 0.801 million a year ago. Basic loss per share from continuing operations was SEK 1.17 compared to SEK 0.18 a year ago. Diluted loss per share from continuing operations was SEK 1.17 compared to SEK 0.18 a year ago.
For the nine months, sales was SEK 2.08 million compared to SEK 3.19 million a year ago. Revenue was SEK 2.72 million compared to SEK 3.46 million a year ago. Net loss was SEK 26.69 million compared to SEK 3.27 million a year ago. Basic loss per share from continuing operations was SEK 3.04 compared to SEK 0.75 a year ago. Diluted loss per share from continuing operations was SEK 3.04 compared to SEK 0.75 a year ago.